Discovery of Plasmepsin Inhibitors by Fragment-Based Docking and Consensus Scoring

被引:44
|
作者
Friedman, Ran [1 ]
Caflisch, Amedeo [1 ]
机构
[1] Univ Zurich, Dept Biochem, CH-8057 Zurich, Switzerland
关键词
antiplasmodial agents; drug discovery; high-throughput docking; malaria; molecular dynamics; HIGH-THROUGHPUT DOCKING; MOLECULAR-DYNAMICS; FORCE-FIELD; ELECTROSTATIC SOLVATION; PLASMODIUM-FALCIPARUM; KINASE INHIBITORS; AQUEOUS-SOLUTIONS; BETA-SECRETASE; ENERGY; MALARIA;
D O I
10.1002/cmdc.200900078
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Plasmepsins (PMs) are essential proteases of the plasmodia parasites and are therefore promising targets for developing drugs against malaria. We have discovered six inhibitors of PM II by high-throughput fragment-based docking of a diversity set of similar to 40000 molecules, and consensus:scoring with force field energy functions. Using the common scaffold of the three most active inhibitors (IC50 = 2-5 mu m), another seven inhibitors were identified by substructure search. Furthermore, these 13 inhibitors belong to at least three different classes of compounds. The in silico approach was very effective since a total of 13 active compounds were discovered by testing only 59 molecules in an enzymatic assay. This hit rate is about one to two orders of magnitude higher than those reported for medium- and high-throughput screening techniques in vitro. Interestingly, one of the inhibitors identified by docking was halofantrine, an antimalarial drug of unknown mechanism. Explicit water molecular dynamics simulations were used to discriminate between two putative binding modes of halofantrine in PM II.
引用
收藏
页码:1317 / 1326
页数:10
相关论文
共 50 条
  • [41] Discovery of Mcl-1 inhibitors using fragment-based methods
    Fesik, Stephen W.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [42] Fragment-Based Discovery of Indole Inhibitors of Matrix Metalloproteinase-13
    Taylor, Steven J.
    Abeywardane, Asitha
    Liang, Shuang
    Muegge, Ingo
    Padyana, Anil K.
    Xiong, Zhaoming
    Hill-Drzewi, Melissa
    Farmer, Bennett
    Li, Xiang
    Collins, Brandon
    Li, John Xiang
    Heim-Riether, Alexander
    Proudfoot, John
    Zhang, Qiang
    Goldberg, Daniel
    Zuvela-Jelaska, Ljiljana
    Zaher, Hani
    Li, Jun
    Farrow, Neil A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (23) : 8174 - 8187
  • [43] Genetically encoded fragment-based discovery
    Derda, Ratmir
    Ng, Simon
    CURRENT OPINION IN CHEMICAL BIOLOGY, 2019, 50 : 128 - 137
  • [44] Deconstructing fragment-based inhibitor discovery
    Babaoglu, Kerim
    Shoichet, Brian K.
    NATURE CHEMICAL BIOLOGY, 2006, 2 (12) : 720 - 723
  • [45] Fragment-Based Lead Discovery and Design
    Joseph-McCarthy, Diane
    Campbell, Arthur J.
    Kern, Gunther
    Moustakas, Demetri
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2014, 54 (03) : 693 - 704
  • [46] Experiences in fragment-based drug discovery
    Murray, Christopher W.
    Verdonk, Marcel L.
    Rees, David C.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2012, 33 (05) : 224 - 232
  • [47] EXPERIENCES IN FRAGMENT-BASED LEAD DISCOVERY
    Hubbard, Roderick E.
    Murray, James B.
    FRAGMENT-BASED DRUG DESIGN: TOOLS, PRACTICAL APPROACHES, AND EXAMPLES, 2011, 493 : 509 - 531
  • [48] The rise of fragment-based drug discovery
    Murray, Christopher W.
    Rees, David C.
    NATURE CHEMISTRY, 2009, 1 (03) : 187 - 192
  • [49] Introduction to Fragment-Based Drug Discovery
    Erlanson, Daniel A.
    FRAGMENT-BASED DRUG DISCOVERY AND X-RAY CRYSTALLOGRAPHY, 2012, 317 : 1 - 32
  • [50] The rise of fragment-based drug discovery
    Murray C.W.
    Rees D.C.
    Nature Chemistry, 2009, 1 (3) : 187 - 192